RGEN$132.14
$132.35
Chart
Performance
Key Stats
AI RGEN Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyRepligen Corporation (RGEN) exhibits a mixed investment profile. Fundamentally, it shows resilience with strong cash flow and a solid balance sheet, though recent profitability has dipped. The company is positioned within the life sciences sector, which has positive thematic tailwinds. Technical indicators are currently mixed, suggesting a period of consolidation or slight downward pressure in the short term. Investors seeking exposure to bioprocessing technologies might find RGEN attractive for its long-term potential, provided they are mindful of current market conditions and recent earnings trends.
Thematic
Repligen operates in the bioprocessing sector, which benefits from the growing demand for biologics and advanced therapies. Key themes include the increasing outsourcing of biopharmaceutical manufacturing, the need for efficient drug development and production technologies, and the overall growth of the life sciences industry. Advancements in gene therapy, cell therapy, and monoclonal antibodies further bolster demand for Repligen's products. ESG considerations are also becoming increasingly important in the life sciences sector, and companies with strong sustainability practices may attract more investment.
Fundamental
Repligen demonstrates financial strength with a healthy cash position and manageable debt. However, recent performance shows a decline in net income and net margins, which warrants attention. The company's valuation metrics, such as P/E and P/S ratios, are somewhat elevated, particularly on a forward-looking basis, suggesting market optimism about future recovery or growth.
Technical
Technical indicators for Repligen are currently mixed. While the stock has shown some short-term positive momentum recently, it remains below its longer-term moving averages. Oscillators suggest it's neither strongly overbought nor oversold, indicating a neutral short-term outlook. Key support and resistance levels will be important to watch.
| Factor | Score |
|---|---|
| Bioprocessing Technologies Demand | 85 |
| Life Sciences Industry Growth | 80 |
| Innovation in Therapeutics | 75 |
| ESG Considerations | 50 |
| Competitive Landscape | 65 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Valuation | 40 |
| Profitability | 35 |
| Growth | 30 |
| Balance Sheet Health | 80 |
| Cash Flow | 85 |
| Cash Position | 90 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Momentum | 50 |
| Momentum | 45 |
| Support & Resistance | 65 |
| Support & Resistance | 70 |
| Volume | 75 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Positive EPS Surprises
Repligen Corporation (RGEN) has shown consistent positive earnings surprises, with reported EPS exceeding estimates in the last several quarters (e.g., +12.95% in Q2 2025, +7.32% in Q1 2025, +28.41% in Q4 2024). This indicates strong execution and better-than-expected operational performance.
Improving Price-to-Sales Ratio
The trailing Price-to-Sales (PS) ratio has decreased from 22.2 in 2021 to 10.8 in 2023, and 12.7 for the full year 2024 (using estimated revenue for 2024). This suggests that the market is valuing the company's sales more reasonably, potentially presenting a more attractive entry point if growth continues.
Bearish Points (8)
Negative Net Income and EPS TTM
The company reported a negative EPS of -0.41 on a trailing twelve months (TTM) basis and a net income of -$28.69 million for the TTM period ending Q4 2024. This indicates current unprofitability, which is a significant risk factor.
High Price-to-Sales (PS) Ratio
Despite the decrease, the PS ratio for 2024 remains high at 12.7. This valuation suggests that investors have high expectations for future revenue growth, and any failure to meet these expectations could lead to a significant price correction.
Calendar
July 2025
29
Next Earnings Date
H: $0.44
A: $0.39
L: $0.35
H: 180.00M
A: 175.05M
L: 168.80M
Profile
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Seasonals
Price Target
179.75 USD
The 39 analysts offering 1 year price forecasts for RGEN have a max estimate of 220.00 and a min estimate of 130.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Direct competitor and partner to Repligen in bioprocessing, offering a comprehensive portfolio of filtration, purification, and cell culture solutions essential for biopharmaceutical manufacturing.
Weight: 95
Parent company of key bioprocessing entities like Cytiva and Pall, which are major players in the same industry segment as Repligen, offering chromatography, filtration, and cell culture media.
Weight: 92
Global leader in scientific instrumentation, reagents, and services with a significant presence in bioprocessing, providing a wide array of tools and consumables for biopharmaceutical production.
Weight: 90
Operates MilliporeSigma, a prominent life science business unit that offers an extensive range of products and services for biopharmaceutical manufacturing, directly competing and partnering with Repligen.